Literature DB >> 9660836

Identification of a novel inhibitor of mitogen-activated protein kinase kinase.

M F Favata1, K Y Horiuchi, E J Manos, A J Daulerio, D A Stradley, W S Feeser, D E Van Dyk, W J Pitts, R A Earl, F Hobbs, R A Copeland, R L Magolda, P A Scherle, J M Trzaskos.   

Abstract

The compound U0126 (1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene) was identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay. U0126 was also shown to inhibit endogenous promoters containing AP-1 response elements but did not affect genes lacking an AP-1 response element in their promoters. These effects of U0126 result from direct inhibition of the mitogen-activated protein kinase kinase family members, MEK-1 and MEK-2. Inhibition is selective for MEK-1 and -2, as U0126 shows little, if any, effect on the kinase activities of protein kinase C, Abl, Raf, MEKK, ERK, JNK, MKK-3, MKK-4/SEK, MKK-6, Cdk2, or Cdk4. Comparative kinetic analysis of U0126 and the MEK inhibitor PD098059 (Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci U. S. A. 92, 7686-7689) demonstrates that U0126 and PD098059 are noncompetitive inhibitors with respect to both MEK substrates, ATP and ERK. We further demonstrate that the two compounds bind to deltaN3-S218E/S222D MEK in a mutually exclusive fashion, suggesting that they may share a common or overlapping binding site(s). Quantitative evaluation of the steady state kinetics of MEK inhibition by these compounds reveals that U0126 has approximately 100-fold higher affinity for deltaN3-S218E/S222D MEK than does PD098059. We further tested the effects of these compounds on the activity of wild type MEK isolated after activation from stimulated cells. Surprisingly, we observe a significant diminution in affinity of both compounds for wild type MEK as compared with the deltaN3-S218E/S222D mutant enzyme. These results suggest that the affinity of both compounds is mediated by subtle conformational differences between the two activated MEK forms. The MEK affinity of U0126, its selectivity for MEK over other kinases, and its cellular efficacy suggest that this compound will serve as a powerful tool for in vitro and cellular investigations of mitogen-activated protein kinase-mediated signal transduction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660836     DOI: 10.1074/jbc.273.29.18623

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  899 in total

1.  Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation.

Authors:  I P Whitehead; Q T Lambert; J A Glaven; K Abe; K L Rossman; G M Mahon; J M Trzaskos; R Kay; S L Campbell; C J Der
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Blockade of NGF-induced neurite outgrowth by a dominant-negative inhibitor of the egr family of transcription regulatory factors.

Authors:  Y Levkovitz; K J O'Donovan; J M Baraban
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways.

Authors:  M A Lawlor; X Feng; D R Everding; K Sieger; C E Stewart; P Rotwein
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

4.  Involvement of the MAP kinase cascade in resetting of the mammalian circadian clock.

Authors:  M Akashi; E Nishida
Journal:  Genes Dev       Date:  2000-03-15       Impact factor: 11.361

5.  A necessity for MAP kinase activation in mammalian spatial learning.

Authors:  J C Selcher; C M Atkins; J M Trzaskos; R Paylor; J D Sweatt
Journal:  Learn Mem       Date:  1999 Sep-Oct       Impact factor: 2.460

Review 6.  Anticancer drug targets: growth factors and growth factor signaling.

Authors:  J B Gibbs
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 7.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.

Authors:  S T Eblen; A D Catling; M C Assanah; M J Weber
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

9.  Hypothermic stress leads to activation of Ras-Erk signaling.

Authors:  E Y Chan; S L Stang; D A Bottorff; J C Stone
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

10.  Activation of the Raf/MAP kinase cascade by the Ras-related protein TC21 is required for the TC21-mediated transformation of NIH 3T3 cells.

Authors:  M Rosário; H F Paterson; C J Marshall
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.